1️⃣ Roche has a second lupus franchise shot with Gazyva
Roche said on April 21 the FDA accepted Gazyva’s SLE filing, with a decision due by December 2026 after Phase 3 ALLEGORY showed a 76.7% SRI-4 response versus 53.5% on placebo.
💡 Why it matters
This has commercial shape already. Roche is trying to turn an aging oncology antibody into a broader autoimmune franchise with real depth.
☕ Coffee talk
If Gazyva works in nephritis and now SLE, how many old oncology antibodies are still under-monetized?
2️⃣ Flagship is trying to make DNA redosable
Flagship launched Serif on April 21 with $50M, pitching a modified DNA platform meant to keep gene expression durable and repeatable without viral vectors or genome integration.
💡 Why it matters
Early, yes, but the bet is clear. If DNA starts behaving more like a repeatable drug than a one-shot therapy, platform value changes fast.
☕ Coffee talk
If this really sits between mRNA and gene therapy, who gets squeezed first?
3️⃣ Medtronic just paid for wire-free coronary physiology
Medtronic closed its CathWorks acquisition on April 20 for $585M plus earn-outs, pulling the AI-based FFRangio system into the portfolio after a 2022 co-promotion and option deal.
💡 Why it matters
This is a workflow bet as much as a device bet. Medtronic wants the diagnostic step inside its own cath-lab stack before the procedure starts.
☕ Coffee talk
If physiology goes software-first in the cath lab, which hardware franchises lose pricing power?